Investor Relations

Latest Financial Results

Q2 2020

Quarter Ended Jun 30, 2020

Latest Annual Filing

Fiscal Year Ended Dec 31, 2019

View Filing

Stock Information

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter

Shareholder Letter

Download Shareholder Letter

Investor Contact Information


Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Investor Relations

Transfer Agent

Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
T: 732-872-2727